Topics

Morphosys ends development of dermatitis treatment, shares fall

03:38 EDT 29 Oct 2019 | Reuters

A development program for an atopic dermatitis treatment has failed, German biotech Morphosys said, sending its shares down 9% in early Frankfurt trade on Tuesday.

Original Article: Morphosys ends development of dermatitis treatment, shares fall

NEXT ARTICLE

More From BioPortfolio on "Morphosys ends development of dermatitis treatment, shares fall"

Quick Search

Relevant Topics

Eczema
Eczema is a common itchy skin disease characterized by reddening and vesicle formation, which may lead to weeping and crusting. It is endogenous, or constitutional. There are five main types; atopic, seborrhoeic, discoid, gravitational or varicose. ...

Biotechnology - Biotech
"using living things to create products or to do tasks for humans" About Biotechnology - Biotech Biotechnology is the practice of using plants, animals and micro-organisms such as bacteria, as well as biological processes - such as the ripen...